Cardiovascular comorbidities in acromegaly
DOI:
https://doi.org/10.12775/JEHS.2021.11.08.030Keywords
acromegaly, cardiovascular comorbidities, hypertension, cardiomyopathy, arrhythmia, heart valve diseaseAbstract
Introduction and purpose: Acromegaly is a rare disease which occurs with the frequency of 0.2-1.1 cases per 100 000 patients per year. The main cause is the excess level of growth hormone (GH) which stimulates the liver to the insulin-like growth factor type 1 (IGF-1) secretion. IGF-1 leads to the tissues overgrowth. In addition, acromegalic patients suffer from many comorbidities, such as: cardiovascular, endocrinological, neoplastic and musculoskeletal complications. The main aim of this review is the update of the latest information concerning cardiovascular comorbidities in patients with acromegaly.
State of knowledge: Studies revealed that 80% of acromegalic patients will develop cardiovascular comorbidities. Complications such as: hypertension, cardiomyopathy, arrhythmia, heart valve disease, atherosclerosis and coronary heart disease as well as myocardial infarction were the most widely described. They are responsible for 44% of deaths in the first decade of the acromegaly and 23% in the second one.
Conclusions: Because of the delayed diagnosis of acromegaly in most patients, most comorbidities are discovered in advanced stages leading to the decrease in patients’ life span. Adequate knowledge about potential complications is necessary to increase patients’ quality of lives.
References
A. Lavrentaki, A. Paluzzi, J. A. H. Wass, and N. Karavitaki, ‘Epidemiology of acromegaly: review of population studies.’, Pituitary. 2017;20(1):4-9. DOI: 10.1007/s11102-016-0754-x.
L. Vilar, C. F. Vilar, R. Lyra, R. Lyra, and L. A. Naves, ‘Acromegaly: clinical features at diagnosis’, Pituitary. 2017;20(1):22-32. DOI: 10.1007/s11102-016-0772-8.
D. S. Greco, ‘Feline acromegaly.’, Top Companion Anim Med. 2012;27(1):31-35. DOI: 10.1053/j.tcam.2012.05.004.
S. Melmed, ‘Acromegaly pathogenesis and treatment.’, The Journal of clinical investigation. 2009;119(11):3189–3202. DOI: 10.1172/JCI39375.
M. R. Ambrosio et al., ‘Acromegaly in the elderly patients.’, Endocrine. 2020;68(1):16-31 DOI: 10.1007/s12020-020-02206-7.
P. Chanson and S. Salenave, ‘Acromegaly.’, Orphanet journal of rare diseases. 2008;3:17. DOI: 10.1186/1750-1172-3-17.
I. M. Holdaway, R. C. Rajasoorya, and G. D. Gamble, ‘Factors influencing mortality in acromegaly.’, J Clin Endocrinol Metab. 2004;89(2):667–674. DOI: 10.1210/jc.2003-031199.
M. Mercado et al., ‘Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic.’, J Clin Endocrinol Metab. 2014;99(12):4438-4446. DOI: 10.1210/jc.2014-2670.
S. Puglisi and M. Terzolo, ‘Hypertension and Acromegaly.’, Endocrinol Metab Clin North Am. 2019;48(4):779–793 DOI: 10.1016/j.ecl.2019.08.008.
M. D. Sharma, A. V. Nguyen, S. Brown, and R. J. Robbins, ‘Cardiovascular Disease in Acromegaly.’, Methodist Debakey Cardiovasc J. 2017;13(2):64–67. DOI: 10.14797/mdcj-13-2-64.
R. N. Clayton, ‘Cardiovascular function in acromegaly.’, Endocr Rev. 2003;24(3):272–277. DOI: 10.1210/er.2003-0009.
M. Ragonese et al., ‘Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction’, Endocrine. 2014;47(1):206–212. DOI: 10.1007/s12020-013-0115-8.
I. M. Holdaway, R. C. Rajasoorya, and G. D. Gamble, ‘Factors influencing mortality in acromegaly’, J Clin Endocrinol Metab. 2004;89(2):667–674. DOI: 10.1210/jc.2003-031199.
M. S. Broder, M. P. Neary, E. Chang, D. Cherepanov, and L. Katznelson, ‘Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases’, Pituitary. 2014;17(4):333–341 DOI: 10.1007/s11102-013-0506-0.
J. Dal et al., ‘Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study’, Eur J Endocrinol. 2016;175(3):181–190. DOI: 10.1530/EJE-16-0117.
S. Puglisi and M. Terzolo, ‘Hypertension and Acromegaly’, Endocrinology and Metabolism Clinics of North America. 2019;48(4):779–793. DOI: 10.1016/j.ecl.2019.08.008.
C. J. Lin, B. B. Mendonca, A. M. Lucon, I. C. Guazzelli, W. Nicolau, and S. M. Villares, ‘Growth hormone receptor messenger ribonucleic acid in normal and pathologic human adrenocortical tissues--an analysis by quantitative polymerase chain reaction technique’, J Clin Endocrinol Metab. 1997;82(8):2671–2676. DOI: 10.1210/jcem.82.8.4159.
P. Kamenicky et al., ‘Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly’, Endocrinology. 2008;149(7):3294–3305. DOI: 10.1210/en.2008-0143.
M. Bielohuby et al., ‘Chronic growth hormone excess is associated with increased aldosterone: a study in patients with acromegaly and in growth hormone transgenic mice’, Exp Biol Med (Maywood). 2009;234(8):1002–1009. DOI: 10.3181/0901-RM-34.
J. A. McKnight et al., ‘Basal and saline-stimulated levels of plasma atrial natriuretic factor in acromegaly’, Clin Endocrinol (Oxf). 1989;31(4):431–438. DOI: 10.1111/j.1365-2265.1989.tb01267.x.
J. Møller, J. O. Jørgensen, J. Marqversen, E. Frandsen, and J. S. Christiansen, ‘Insulin-like growth factor I administration induces fluid and sodium retention in healthy adults: possible involvement of renin and atrial natriuretic factor’, Clin Endocrinol (Oxf). 2000;52(2):181–186. DOI: 10.1046/j.1365-2265.2000.00931.x.
J. Słowińska-Srzednicka, S. Zgliczyński, P. Soszyński, W. Zgliczyński, and W. Jeske, ‘High blood pressure and hyperinsulinaemia in acromegaly and in obesity’, Clin Exp Hypertens A. 1989;11(3):407–425. DOI: 10.3109/10641968909035351.
T. Ikeda et al., ‘Correlation between blood pressure and plasma insulin in acromegaly’, J Intern Med. 1993;234(1):61–63. DOI: 10.1111/j.1365-2796.1993.tb00705.x.
V. Ronconi et al., ‘Reduced nitric oxide levels in acromegaly: cardiovascular implications’, Blood Press. 2005;14(4):227–232. DOI: 10.1080/08037050510034293.
M. Bondanelli, M. R. Ambrosio, and E. C. degli Uberti, ‘Pathogenesis and prevalence of hypertension in acromegaly’, Pituitary. 2001;4(4):239–249. DOI: 10.1023/a:1020798430884.
F. Bogazzi et al., ‘High prevalence of cardiac hypertophy without detectable signs of fibrosis in patients with untreated active acromegaly: an in vivo study using magnetic resonance imaging’, Clinical Endocrinology. 2008;68(3):361–368. DOI: 10.1111/J.1365-2265.2007.03047.X.
L. JT, ‘Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients’, American heart journal. 1980;100(1):41–52. DOI: 10.1016/0002-8703(80)90277-X.
A. Colao, P. Marzullo, C. Di Somma, and G. Lombardi, ‘Growth hormone and the heart’, Clinical Endocrinology. 2001;54(2):137–154. DOI: 10.1046/J.1365-2265.2001.01218.X.
N. S. Freestone, S. Ribaric, and W. T. Mason, ‘The effect of insulin-like growth factor-1 on adult rat cardiac contractility’, Molecular and Cellular Biochemistry 1996 163:1. 1996;163(1):223–229. DOI: 10.1007/BF00408662.
F. ML et al., ‘Myocardial hypertrophy in transgenic mice overexpressing the bovine growth hormone (bGH) gene’, Journal of internal medicine. 2000;247(5):546–552. DOI: 10.1046/J.1365-2796.2000.00651.X.
H. Gouya et al., ‘Rapidly Reversible Myocardial Edema in Patients with Acromegaly: Assessment with Ultrafast T2 Mapping in a Single-Breath-Hold MRI Sequence’, http://dx.doi.org/10.2214/AJR.07.2031. 2012;190(6):1576–1582. DOI: 10.2214/AJR.07.2031.
G. MD, V. N, Y. S, and F. WH, ‘Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options’, Cardiology in review. 2018;26(6):307–311 DOI: 10.1097/CRD.0000000000000215.
L. Saccà, R. Napoli, and A. Cittadini, ‘Growth hormone, acromegaly, and heart failure: an intricate triangulation’, Clinical Endocrinology. 2003;59(6):660–671. DOI: 10.1046/J.1365-2265.2003.01780.X.
R.-L. AM and M. M, ‘Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management’, Endocrine. 2017;55(2):346–359. DOI: 10.1007/S12020-016-1191-3.
A. B et al., ‘Evaluation of left ventricular diastolic function according to new criteria and determinants in acromegaly’, International heart journal. 2012;53(5):299–305, 2012. DOI: 10.1536/IHJ.53.299.
B. H et al., ‘Long-term outcome of patients with acromegaly and congestive heart failure’, The Journal of clinical endocrinology and metabolism. 2004;89(11):5308–5313. DOI: 10.1210/JC.2004-0821.
I. J, A. M, K. K, and C. A, ‘GH and the cardiovascular system: an update on a topic at heart’, Endocrine. 2015;48(1):25–35. DOI: 10.1007/S12020-014-0327-6.
P. M, D. F, V. R, and M. P, ‘Acromegaly and ultrasound: how, when and why?’, Journal of endocrinological investigation. 2020;43(3):279–287. DOI: 10.1007/S40618-019-01111-9.
A. Colao, D. Ferone, P. Marzullo, and G. Lombardi, ‘Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management’, Endocrine Reviews. 2004;25(1):102–152. DOI: 10.1210/ER.2002-0022.
M. B et al., ‘Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly’, The Journal of clinical endocrinology and metabolism. 1993;77(3):790–793. DOI: 10.1210/JCEM.77.3.8370700.
K. G et al., ‘Arrhythmia profile in acromegaly’, European heart journal. 1992;13(1):51–56. DOI: 10.1093/OXFORDJOURNALS.EURHEARTJ.A060047.
O. A et al., ‘Increased Short-Term Beat-To-Beat Variability of QT Interval in Patients with Acromegaly’, PloS one. 2015;10(4). DOI: 10.1371/JOURNAL.PONE.0125639.
M. P et al., ‘Late potentials and ventricular arrhythmias in acromegaly’, International journal of cardiology. 2005;104(2):197–203. DOI: 10.1016/J.IJCARD.2004.12.010.
K. A et al., ‘Left ventricular synchronicity is impaired in patients with active acromegaly’, Endocrine. 2013;44(1):200–206. DOI: 10.1007/S12020-012-9859-9.
de J. S, van V. TA, van R. HV, and de B. JM, ‘Fibrosis and cardiac arrhythmias’, Journal of cardiovascular pharmacology. 2011;57(6):630–638. DOI: 10.1097/FJC.0B013E318207A35F.
C. S et al., ‘Meta-analysis of left ventricular hypertrophy and sustained arrhythmias’, The American journal of cardiology. 2014;114(7):1049–1052. DOI: 10.1016/J.AMJCARD.2014.07.015.
W. L et al., ‘Low frequency of cardniac arrhythmias and lack of structural heart disease in medically-naïve acromegaly patients: a prospective study at baseline and after 1 year of somatostatin analogs treatment’, Pituitary. 2016;19(6):582–589. DOI: 10.1007/S11102-016-0749-7.
A. Colao et al., ‘High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study.’, J Clin Endocrinol Metab. 2003;88(7):3196–3201. DOI: 10.1210/jc.2002-021099.
A. M. Ramos-Leví and M. Marazuela, ‘Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them?’, Front Endocrinol (Lausanne). 2019;10:120, 2019. DOI: 10.3389/fendo.2019.00120.
A. M. Ramos-Leví and M. Marazuela, ‘Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management.’, Endocrine. 2017;55(2):346–359. DOI: 10.1007/s12020-016-1191-3.
P. Pereira, F. Duarte, R. Lamas, and R. Vaz, ‘Idiopathic spinal cord herniation: case report and literature review.’, Acta Neurochir (Wien). 2001;143(4):401–406. DOI: 10.1007/s007010170096.
H. Yang, H. Tan, H. Huang, and J. Li, ‘Advances in Research on the Cardiovascular Complications of Acromegaly.’, Front Oncol. 2021;11:640999. DOI: 10.3389/fonc.2021.640999.
A. A. van der Klaauw et al., ‘Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation.’, Growth Horm IGF Res. 2006;16(2):101–107. DOI: 10.1016/j.ghir.2006.02.002.
I. Kartal et al., ‘Investigation of early atherosclerotic changes in acromegalic patients.’, Int J Clin Pract. 2010;64(1):39–44. DOI: 10.1111/j.1742-1241.2008.01750.x.
F. Fischer et al., ‘Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease.’, Clin Endocrinol (Oxf). 2004;61(5):595–602. DOI: 10.1111/j.1365-2265.2004.02136.x.
C. Berg et al., ‘Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control.’, J Clin Endocrinol Metab. 2010;95(8):3648–3656. DOI: 10.1210/jc.2009-2570.
F. Bogazzi et al., ‘Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study.’, J Clin Endocrinol Metab. 2007;92(11):4271–4277. DOI: 10.1210/jc.2007-1213.
H. Akutsu et al., ‘Acromegaly per se does not increase the risk for coronary artery disease.’, Eur J Endocrinol. 2010;162(5):879–886. DOI: 10.1530/EJE-09-0945.
P. Petrossians et al., ‘Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database’, Endocr Relat Cancer. 2017;24(10):505–518. DOI: 10.1530/ERC-17-0253.
C. COURVILLE and V. R. MASON, ‘THE HEART IN ACROMEGALY’, Archives of Internal Medicine. 1938;61(5):704–713. DOI: 10.1001/archinte.1938.00180100014002.
B. L. Herrmann et al., ‘Occurrence of ventricular late potentials in patients with active acromegaly.’, Clin Endocrinol (Oxf). 2001;55(2):201–207. DOI: 10.1046/j.1365-2265.2001.01319.x.
T. Kendzerska, A. S. Gershon, G. Hawker, R. S. Leung, and G. Tomlinson, ‘Obstructive sleep apnea and risk of cardiovascular events and all-cause mortality: a decade-long historical cohort study.’, PLoS Med. 2014;11(2):1001599. DOI: 10.1371/journal.pmed.1001599.
H. Nakashima et al., ‘Obstructive sleep apnoea increases the incidence of morning peak of onset in acute myocardial infarction.’, Eur Heart J Acute Cardiovasc Care. 2013;2(2):153–158. DOI: 10.1177/2048872613478557.
S. Cannavo et al., ‘Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.’, J Clin Endocrinol Metab. 2006;91(10):3766–3772. DOI: 10.1210/jc.2005-2857.
C. Schöfl et al., ‘Incidence of myocardial infarction and stroke in acromegaly patients: results from the German Acromegaly Registry.’, Pituitary. 2017;20(6):635–642. DOI: 10.1007/s11102-017-0827-5.
Downloads
Published
How to Cite
Issue
Section
License
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 550
Number of citations: 0
